Biopharmaceutical company Hansa Medical AB (STO:HMED) reported on Wednesday a change in the number of votes in the company as a result of conversion of in total 70,739 C shares into ordinary shares carried out in January 2018.
Reportedly, these conversion were carried out under Hansa Medical's long-term incentive programme.
As of 31 January 2018, the total number of registered and outstanding shares of Hansa Medical amounted to 38,208,386 of which 37,878,125 were ordinary shares, together carrying 37,878,125 votes, and 330,261 were C shares, together carrying 33,026.1 votes.
The total number of votes in Hansa Medical is 37,911,151.1.
Hansa Medical is developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases.
Roivant to announce Q3 2026 financial results
HUTCHMED reports positive Phase III results for sovleplenib in wAIHA
Physiomics secures follow-on UK contract for Phase 2 study support
Amgen's UPLIZNA receives US FDA approval
Physiomics secures new contract with Numab Therapeutics for preclinical antibody development
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
AstraZeneca to invest USD2bn in major Maryland manufacturing expansion
European Commission approves Celltrion's Remsima IV liquid formulation
TIRmed Pharma partners with Bachem to advance production of atopic dermatitis therapy
Fondazione Telethon reports positive opinion for Waskyra marketing authorisation in Europe
Vascarta and CUNY report positive preclinical results in glioblastoma treatment